Reaction
Immune-Mediated Uveitis reporting signals
As of the last recalculation, Immune-Mediated Uveitis appears in 178 FAERS reports alongside 3 co-occurring drug terms. The strongest observed disproportionality signal is NIVOLUMAB (PRR 505.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Nivolumab | 125 | 505.4 | 506.1 |
| Ipilimumab | 79 | 384.0 | 384.7 |
| Pembrolizumab | 50 | 76.9 | 76.9 |